Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: First Tin chairman raises stake

(Sharecast News) - First Tin revealed on Tuesday that chairman Charles Brookes had acquired 360,000 ordinary shares in the tin development company. Brookes, who snapped up the shares via his 50% interest in Arlington Group Asset Management, purchased the shares on Monday at an average price of 5.0p each, for a total value of £18,000.

Following the transaction, Brookes holds a beneficial interest in 34.07m ordinary First Tin shares, representing approximately 10.7% of the company's issued share capital.

As of 1600 BST, First Tin shares were up 1.54% at 5.28p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Oakley Capital Investments Ltd. (di) (OCI) Director name: Beck,Fiona Amount purchased: 10,000 @ 509.00p Value: £50,900.00

First Tin (1SN) Director name: Brookes,Charles Cannon Amount purchased: 360,000 @ 5.00p Value: £18,000.00

Top Director Sells

Share this article

Related Sharecast Articles

Director dealings: Essentra CEO raises stake
(Sharecast News) - Essentra revealed on Wednesday that chief execuitve Scott Fawcett had acquired 17,483 ordinary shares in the FTSE 250-listed hardware manufacturer.
Director dealings: AB Dynamics CEO snaps up shares
(Sharecast News) - AB Dynamics revealed on Tuesday that chief executive Sarah Matthews-DeMers had acquired 2,000 ordinar shares in the AIM-listed automotive testing and development solution supplier.
Director dealings: Bioventix chairman raises stake
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.
Director dealings: Bioventix chairman raises stake
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.